SynthesisFrontiers in pharmacology2025
Traditional herbal medicine for the prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis with association rule analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This systematic review and meta-analysis evaluated the preventive efficacy and safety of orally-administered traditional herbal medicine (THM) for the management of chemotherapy-induced peripheral neuropathy (CIPN) in patients with cancer. Methods: Randomized controlled trials (RCTs) evaluating the efficacy of orally-administered THM in the prevention of CIPN published up to 30 April 2024 were retrieved from nine databases. The primary outcome was the incidence of CIPN, and the secondary outcomes included changes in neuropathic pain intensity, nerve conduction study parameters, Karnofsky Performance Scale (KPS) scores, and the incidence of adverse events. The quality of the studies and the strength of the evidence were evaluated using the Cochrane Risk of Bias Assessment Tool and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method. Key herbal combinations were identified by conducting an association rule analysis. Results: Thirty-seven RCTs involving 2,882 patients were included. Significant differences were observed between THM and the placebo [RR 0.83, 95% CI 0.74-0.93, p < 0.05; low quality of evidence], usual care [RR 0.51, 95% CI 0.37-0.69, p < 0.05; moderate quality of evidence], and no treatment [RR 0.62, 95% CI 0.54-0.71, p < 0.05; moderate quality of evidence] in terms of in the incidence rate of CIPN. A significant reduction in the intensity of neuropathic pain [SMD -0.81, 95% CI -1.07 to -0.56, p < 0.05; high quality of evidence] and a significant improvement in KPS [MD 8.18, p < 0.05; low quality of evidence] were observed in the THM compared to no treatment. Furthermore, compared with usual care and no treatment, the use of THM yielded a significant improvement in the nerve conduction parameters with low quality of evidence. No serious adverse events were reported. The combination of Astragali Radix and Cinnamomi Ramulus as the strongest herbal combination used for the prevention of CIPN. Conclusion: THM may be a promising option for the prevention of CIPN in patients with cancer. Low certainty of evidence, and substantial heterogeneity and risk of bias can limit the strength of the conclusions. Further well-designed and rigorously reported randomized controlled trials are warranted to confirm these findings and clarify their clinical applicability. Systematic Review Registration: https://www.crd.york.ac.uk/prospero, Identifier: CRD42021270942.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.